Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.1K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.1K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

1.8K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.8K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.0K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.0K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

4.2K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.2K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zone of z-scores uncertainty in pulmonary function interpretation: A proof-of-concept study from CO and NO lung diffusing capacities.

Respiratory medicine·2025
Same author

Enhanced detection of patients with previous COVID-19: superiority of the double diffusion technique.

BMJ open respiratory research·2025
Same author

Pulmonary diffusing capacity and dyspnoea following COVID-19: Insights from multicentre datasets.

Data in brief·2025
Same author

Effects of increasing tidal volume and end-expiratory lung volume on induced bronchoconstriction in healthy humans.

Respiratory research·2024
Same author

On the Assessment of Preserved Ratio Impaired Spirometry.

American journal of respiratory and critical care medicine·2023
Same author

Reply to: Lung pathophysiology in patients with long COVID-19: one size definitely does not fit all.

ERJ open research·2023

Related Experiment Video

Updated: Mar 14, 2026

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

3.9K

Beta-Adrenergic Agonists.

Giovanni Barisione1, Michele Baroffio2, Emanuele Crimi3

  • 1Preventive and Occupational Medicine Unit, Respiratory Pathophysiology Laboratory, University Hospital San Martino, Largo R. Benzi, 10 - 16132 Genoa, Italy. giovanni.barisione@hsanmartino.it.

Pharmaceuticals (Basel, Switzerland)
|October 8, 2016
PubMed
Summary

Inhaled beta2-adrenoceptor (β₂-AR) agonists are crucial for asthma treatment, relieving symptoms and controlling disease. This review details their mechanisms, signaling, and safety concerns in asthma management.

Keywords:
G-protein-coupled receptor signalingairway smooth musclebronchodilationdesensitizationsafety issuesβ2-adrenoceptors

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K
Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

10.4K

Related Experiment Videos

Last Updated: Mar 14, 2026

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

3.9K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K
Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues
08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

10.4K

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Molecular Biology

Background:

  • Inhaled beta2-adrenoceptor (β₂-AR) agonists are cornerstone bronchodilators for asthma, serving as both rescue and controller medications.
  • Understanding the β₂-adrenergic system's role in airway smooth muscle tone is critical for asthma pathophysiology.
  • Recent safety concerns necessitate a thorough review of these widely used asthma medications.

Approach:

  • Review of basic mechanisms of β₂-adrenergic system in airway smooth muscle.
  • Detailed description of β₂-AR structure and G-protein-coupled receptor signaling.
  • Examination of β₂-AR desensitization and dysfunction, including phosphorylation pathways.

Key Points:

  • The β₂-adrenergic system regulates airway smooth muscle tone.
  • β₂-AR structure and signaling involve complex molecular pathways, including G-protein coupling.
  • Phosphorylation by protein kinase A and β-adrenergic receptor kinase mediates receptor desensitization.

Conclusions:

  • Inhaled β₂-AR agonists are indispensable in asthma management.
  • Understanding receptor signaling and desensitization is key to optimizing asthma therapy.
  • Ongoing evaluation of the safety profile of inhaled β₂-AR agonists is essential.